Capricor investors can seek lead plaintiff role in securities suit
Schall, Brown & Schwartz LLP says investors who bought Capricor Therapeutics shares during a listed class period may seek lead-plaintiff status in a securities lawsuit over Deramiocel and the FDA review process.
Schall, Brown & Schwartz LLP said on Aug. 17 that investors who bought Capricor Therapeutics Inc. shares during a listed class period may seek lead-plaintiff status in a securities class action over the company’s statements about Deramiocel and the FDA review process.
According to the PR Newswire release, the lawsuit covers investors who traded Capricor stock between Dec. 17, 2025, and July 26, 2026. The notice says lead-plaintiff status is not required to share in any recovery if the case moves forward.
What happened
The release says the lawsuit alleges violations of Section 10(b), Section 20(a), and SEC Rule 10b-5 under the Securities Exchange Act of 1934. It says the complaint accuses Capricor of making false and misleading statements to the market.
According to the firm, the allegations focus on the company’s handling of clinical data related to Deramiocel, including a change to the statistical analysis plan used to analyze that data. The release says the FDA had not agreed to changes from the pre-specified plan before Capricor resubmitted its Biologics License Application, or BLA, for the treatment.
Background
Capricor Therapeutics trades on Nasdaq under the ticker CAPR. The release identifies the class period as Dec. 17, 2025, through July 26, 2026.
The firm says investors who purchased CAPR shares during that span are encouraged to contact Schall, Brown & Schwartz LLP about possible lead-plaintiff appointment. It also says investors do not need to be named lead plaintiff to take part in any recovery.
What the firm said
The release does not include a response from Capricor. It lists Brian Schall and David Schwartz as contacts for the firm in Los Angeles and says the firm specializes in securities class actions and shareholder rights litigation.
What happens next
The release says interested investors may contact the firm for more information about lead-plaintiff status. It does not give a court date or other next procedural step.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
View the Web StoryA visual, tap-through version of this reportThis is the AMP version of the article. Read the full article on Atlas Watchline.